Thomas Ferry
Pulmonary Disease · Greensburg, INNPI 1194726406
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $18,188 of the $27,623 with a category attached, or 65.8%. Edwards Lifesciences accounts for 65.8% of it on its own, with 28 other manufacturers making up the rest. Reporting peaked in 2019 at $9,967 and has fallen 92.8% since, to $721 in 2025. Among pulmonary disease clinicians in IN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 405 payments — averaging $68.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$18K
- AstraZeneca$3K
- GSK$2K
- Grifols Shared Services North America, Inc.$764
- Grifols USA, LLC$702
- Mallinckrodt Hospital Products Inc.$370
- plus $3K from 23 others
What the payments were for
- Consulting fees$18,18866%
- Food & beverage$9,33634%
- Education$1000%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 38 | $18,188 |
| AstraZeneca | 97 | $2,894 |
| GSK | 99 | $2,197 |
| Grifols Shared Services North America, Inc. | 7 | $764 |
| Grifols USA, LLC | 27 | $702 |
| Mallinckrodt Hospital Products Inc. | 14 | $370 |
| Sanofi | 14 | $329 |
| Mylan Specialty L.p. | 17 | $325 |
| Boehringer Ingelheim | 24 | $303 |
| Regeneron Healthcare Solutions, Inc. | 6 | $256 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $248 |
| Philips North America LLC | 10 | $165 |
| Insmed, Inc. | 2 | $154 |
| Boston Scientific | 1 | $120 |
| United Therapeutics Corporation | 5 | $117 |
| Pfizer | 3 | $73 |
| Amgen | 4 | $70 |
| Electromed, Inc. | 7 | $62 |
| Advanced Respiratory, Inc | 3 | $55 |
| Mallinckrodt Enterprises LLC | 3 | $38 |
| Shire North American Group Inc | 3 | $37 |
| Actelion Pharmaceuticals US, Inc. | 2 | $36 |
| ITF Therapeutics LLC | 1 | $25 |
| Octapharma USA, Inc. | 1 | $19 |
| Novartis | 1 | $18 |
| Merck | 1 | $17 |
| Vifor Pharma, Inc. | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $14 |
| Bayer | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Prolastin-C Liquid$863
- NUCALA$692
- TEZSPIRE$373
- DUPIXENT$356
- BREZTRI$254
- TRELEGY ELLIPTA$246
- FASENRA$227
- Prolastin-C$160
- Arikayce$140
- AIRSUPRA$132
- COREDX$120
How this compares
$27,623 in reported general payments places this provider in the 90th percentile of 258 pulmonary disease providers in Indiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 247 | $200,358 |
| OpsumitMacitentan | 11 | $138,078 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 207 | $137,256 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 66 | $37,040 |
| Breo ElliptaFluticasone/Vilanterol | 60 | $31,210 |
| Pirfenidone | 21 | $16,235 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 27 | $14,015 |
| Roflumilast | 77 | $8,201 |
| SymbicortBudesonide/Formoterol Fumarate | 18 | $5,908 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 154 | $4,505 |
| Theophylline ErTheophylline Anhydrous | 28 | $2,417 |
| Azithromycin | 133 | $1,269 |
| Montelukast Sodium | 181 | $1,267 |
| Levalbuterol Tartrate HfaLevalbuterol Tartrate | 28 | $980 |
| CefuroximeCefuroxime Axetil | 41 | $732 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $2,197 | $245,583334 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $2,894 | $143,165225 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $36 | $138,07811 claims |
| Boehringer IngelheimStiolto Respimat | $303 | $37,04066 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 258 pulmonary disease providers in Indiana.
Other pulmonary disease in Greensburg
- David MaresAnderson$1.3M
- David WilsonSeymour$689K
- Giovanni InfusinoCrown Point$526K
- Ajay DeshpandeTerre Haute$304K
- Faisal KhanGreenwood$207K
- Sandeep KukrejaGreenwood$206K
- Raja DevanathanHobart$193K
- Asaad JandaliMunster$161K
- Gaurav KumarPortage$102K
- Rajeev MehtaMuncie$88K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.